There is increasing evidence that combination therapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) and programmed cell death protein 1 (PD-1) inhibitor is safe and efficacious in treating many types of malignant tumors. However, clinical data demonstrating the effect of this treatment combination for patients with metastatic soft tissue sarcoma (STS) are currently limited. | Tian et al. BMC Cancer 2022 22 56 https s12885-022-09176-1 RESEARCH Open Access Nanoparticle albumin-bound paclitaxel and PD-1 inhibitor sintilimab combination therapy for soft tissue sarcoma a retrospective study Zhichao Tian1 Shuping Dong1 Yang Yang2 Shilei Gao1 Yonghao Yang3 Jinpo Yang4 Peng Zhang1 Xin Wang1 and Weitao Yao1 Abstract Background There is increasing evidence that combination therapy with nanoparticle albumin-bound paclitaxel nab-paclitaxel and programmed cell death protein 1 PD-1 inhibitor is safe and efficacious in treating many types of malignant tumors. However clinical data demonstrating the effect of this treatment combination for patients with metastatic soft tissue sarcoma STS are currently limited. Methods The clinical data of patients with metastatic STS who received nab-paclitaxel plus PD-1 inhibitor sintili- mab therapy between January 2019 and February 2021 were retrospectively analyzed. The effectiveness and safety of the combined treatment were evaluated in terms of the median progression-free survival PFS estimated using the Kaplan Meier method. The univariate Cox proportional hazards model was used to analyze the relationship between clinicopathological parameters and PFS. All statistical analyses were two-sided P Tian et al. BMC Cancer 2022 22 56 Page 2 of 9 Keywords Nanoparticle albumin-bound paclitaxel PD-1 inhibitor Programmed cell death protein 1 Sintilimab Soft tissue sarcoma Angiosarcoma Background of patients with advanced STS using nab-paclitaxel or Soft tissue sarcomas STSs are malignant tumors origi- PD-1 inhibitors 26 27 . Some patients were treated with nating from the mesenchymal tissue. This type of tumor nab-paclitaxel plus a PD-1 inhibitor. In this study we ret- occurs throughout the body and is typically characterized rospectively collected and analyzed the clinical data of by an asymptomatic mass. Some STSs that grow too fast patients with advanced STS who were treated with nab- can cause pain by
